Aerogen

Ireland - GalwayBiotechnology1 H-1B visas (FY2023)

Focus: Aerogen is a respiratory-focused biotechnology company headquartered in Galway, Ireland, specializing in nebulizer device technology and inhaled drug formulations for acute and chronic respiratory diseases.

Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Aerogen

AI assessmentNot Hiring

No open roles listed right now. Follow Aerogen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

nebulizer devices

Chronic Obstructive Pulmonary Disease

Growth

Core platform technology enabling delivery of multiple pipeline compounds; 4 active trials demonstrate commercial validation strategy.

Pipeline & Clinical Trials

Help build intelligence for Aerogen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline of 6 respiratory programs spanning Phase 1 through Phase 3, with SF-RI 1 surfactant in Phase 3 for Respiratory Distress Syndrome representing a near-term value catalyst
Unique technology platform in nebulizer devices (4 active COPD trials) positions the company at the intersection of device and pharma, offering diverse technical career paths
Emerging respiratory therapeutics portfolio addressing high-unmet-need indications including acute respiratory failure, pneumonia, and COVID-19

Watch Out For

Zero active job openings at time of data collection suggests minimal hiring activity and potential organizational constraints
Limited public financial transparency (no revenue, R&D spend, or cash position data available) makes it difficult to assess long-term stability and career growth investment

Generated by Claude from Aerogen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Jet Nebuliser

COPD Exacerbation

N/A

Clinical Trials (1)

NCT04181073Borg Score Outcomes in Respiratory Compromised Acute Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Treatment Via Vibrating Mesh Nebuliser Versus Jet Nebuliser in the Emergency Department

N/A

nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen

Hypoxemic Respiratory Failure

N/A

Clinical Trials (1)

NCT05880836In Line Aerosol Nebulization With High Flow

N/A

nebulizer devices

COPD

N/A

Vibrating Mesh Nebuliser

Chronic Obstructive Pulmonary Disease

N/A

Clinical Trials (1)

NCT03286855Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)

N/A

Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser

Respiratory Failure

N/A

Clinical Trials (1)

NCT05635903Jet or Vibrating Mesh Nebulisation for Secretion Management in ICU

N/A

Albuterol Sulfate, 2.5 Mg/3 mL

Chronic Obstructive Pulmonary Disease

Phase 1

Clinical Trials (1)

NCT06271408Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Phase 1

caspofungin

Pneumocystis Pneumonia

Phase 1/2

Clinical Trials (1)

NCT06892951CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

Phase 1/2

AeroFact

Respiratory Distress Syndrome

Phase 2

Clinical Trials (1)

NCT03969992A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Phase 2

epoprostenol

COVID-19

Phase 2

Clinical Trials (2)

NCT03122730VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Phase 2

NCT04452669VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

Phase 2

salbutamol

Acute Respiratory Failure

Phase 2/3

Clinical Trials (2)

NCT06815679Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC

Phase 2/3

NCT02686086A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD

N/A

SF-RI 1 surfactant

Respiratory Distress Syndrome

Phase 3

Clinical Trials (1)

NCT06776783Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 12 clinical trials

Top TAs: Respiratory, Infectious Diseases, Cardiovascular

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

9 pipeline

Infectious Diseases

3 pipeline

Cardiovascular

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub